Low Density Lipoprotein (LDL) News and Research

RSS

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

GI Dynamics, Inc. announced today that clinical data about EndoBarrier Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, was presented at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) in San Diego.

23 Jun 2012

Health care system or patient-directed programs help prevent or manage diabetes

A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.

23 Jun 2012

LDL particles may be a more accurate measure of early-stage atherosclerosis

LipoScience, Inc., today announced publication of a clinical study in the current issue of Atherosclerosis suggesting that low density lipoprotein (LDL) particles may be a more accurate measure of early-stage (subclinical) atherosclerosis than LDL cholesterol among retired National Football League (NFL) players.

19 Jun 2012

Bioactive compounds in peaches, plums and nectarines can fight-off diabetes, cardiovascular disease

Peaches, plums and nectarines have bioactive compounds that can potentially fight-off obesity-related diabetes and cardiovascular disease, according to new studies by Texas AgriLife Research.

19 Jun 2012

Individuals on statins more likely to experience fatigue with exertion

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.

12 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Women may need stronger lipid-lowering regimens

Women who are at high risk for cardiovascular disease are significantly less likely to achieve their lipid-lowering treatment goals than their male counterparts, show findings from a Chinese study.

7 Jun 2012

ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24.

7 Jun 2012

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced results from a clinical study demonstrating that patients with normal levels of lipoprotein(a) may retain significant risk of atherosclerosis due to an elevated low density lipoprotein particle (LDL-P) number.

2 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

BHD launches Statin Induced Myopathy Genotype test

Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation.

31 May 2012

Million Hearts, ACP aim to prevent heart attacks and strokes in five years

The American College of Physicians (ACP), the second-largest physician group in the United States, has joined Million Hearts, a public-private sector initiative that aims to prevent one million heart attacks and strokes in five years. Million Hearts has two primary goals:

30 May 2012

FDA accepts NDA filing for KYNAMRO to treat HoFH

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced today that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for KYNAMRO (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

29 May 2012

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH).

28 May 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

Research roundup: Do mandatory screening laws affect disparities?; Mass. health law, 6 years later

Since Massachusetts passed its own expansive health law, the state's uninsured rate has dropped and access to care has dramatically improved. But as this brief notes, two major issues remain. Massachusetts will have to find ways to contain health care costs -- now under discussion in the state legislature -- as well as align itself with the federal health law. In the process, other states "can draw on some of the state's early successes and challenges"

25 May 2012

Workout routine tips from NewYork-Presbyterian Hospital/CUMC

The summer is a great season for getting in shape. Whether by playing a sport, doing an aerobic exercise routine, or just returning to that familiar running path — this is the time for activity.

14 May 2012

'Good' cholesterol may not protect against coronary heart disease

A new study by Harvard School of Public Health (HSPH) researchers has found that a subclass of high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not protect against coronary heart disease (CHD) and in fact may be harmful.

8 May 2012